CYTK · earnings call history
Cytokinetics Q2 FY26 — Strong MYQORZO Launch Momentum and Expanded Aficamten Pipeline Opportunities
Read the briefCytokinetics Q1 FY26 — Strong MYQORZO Launch and Positive ACACIA-HCM Results
Read the briefCytokinetics Q4 FY25 — Myqorzo Global Approvals and Commercial Launch Underway
Read the briefBrowse all US companies on the earnings-call register.